Nine of 44 (20.4%) patients with HER2-positive tumor had serum anti-HER2 AAbs, whereas only 3/63 (4.8%) patients with HER2-negative tumor had serum anti-HER2 AAbs (P = .03). The gene discussed is ERBB2; the disease is neoplasm.